Stockscreener 앱 받기
853.82
2.15%
-18.76
Argen X Se Adr 주식(ARGX)의 최신 뉴스
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June - Benzinga
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance UK
argenx to buy Forte Biosciences in a deal worth $2.2 billion - grafa.com
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket - Benzinga
Argenx to buy Forte Biosciences for $2.2 billion to expand immunology pipeline - Investing.com UK
Weekly Recap: Q2 sales and profit surge and Empasiprubart readout schedule - TradingView
argenx SE Sponsored ADR Revenue Breakdown – DUS:1AEA - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX) - The Globe and Mail
argenx SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
RBC Capital raises argenx stock price target to $1,025 on strong Vyvgart sales - Investing.com
H.C. Wainwright reiterates argenx stock rating on strong sales - Investing.com
Guggenheim raises argenx stock price target to $1,185 on strong sales - Investing.com
Citizens cuts argenx stock price target to $932 on valuation - Investing.com
Argenx's Robust Vyvgart Growth Drives Margin Expansion as Pipeline Advances - Morningstar
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
European ADRs Slipped In US Trading Late Thursday - Finimize
argenx Q2 2026 slides: 60% sales growth, seronegative gMG expansion - Investing.com
argenx ADR earnings beat by $0.97, revenue topped estimates - Investing.com
Argenx soars on strong Vyvgart sales, beating estimates By Investing.com - Investing.com Canada
Argenx shares jump on Vyvgart sales beat, pipeline readouts ahead By Investing.com - Investing.com Nigeria
Argenx soars on strong Vyvgart sales, beating estimates - Investing.com
argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances By GuruFocus - Investing.com Canada
BR:A1RG34 Stock Latest News - TipRanks
Argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update - marketscreener.com
Argenx Se (ARGX) Receives a Buy from Guggenheim - The Globe and Mail
ARGENX : Receives a Buy rating from Deutsche Bank - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Argenx stock trades steady as pipeline progress follows pivotal transplant data - Ad-hoc-news.de
Argenx stock steadies as investors digest Q1 2026 Vyvgart growth and cash position - Ad-hoc-news.de
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
VCRE|Vicore Pharma Holding AB ADR|Price:11.920|Chg%:-0.460 - TradingKey
Argenx : argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 - marketscreener.com
argenx SE (ARGNF) Stock Price, News, Quote & History - Yahoo Finance
Argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 - marketscreener.com
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB) - The Globe and Mail
RBC Capital Adjusts argenx SE ADR Price Target to $945 From $890, Maintains Outperform Rating - marketscreener.com
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point - Investor's Business Daily
Argenx, stock of the day, eyes buy point amid triple-digit growth - MSN
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - Investor's Business Daily
Argenx stock holds the focus on its global immunology franchise. - Ad-hoc-news.de
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Nigeria
ARGXArgen X SE ADR Options - Finviz
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx stock hits all-time high at 934.69 USD By Investing.com - Investing.com Nigeria
Argenx stock hits all-time high at 934.69 USD - Investing.com
BofA raises argenx stock price target to $1,088 on myositis data - Investing.com South Africa
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth - Investor's Business Daily
A2H9WD Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
argenx SE Sponsored ADR Actuals & Estimates (NASDAQ:ARGX) - TradingView
H.C. Wainwright reiterates argenx stock rating on myositis trial update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates argenx stock rating on myositis trial update - Investing.com
2.41%
0.02%
자본화:
|
볼륨(24시간):